Editorial Board
Adam Wysokinski
Central Clinical Hospital, Lodz, Poland · poland
Editorial leadership for Journal of Schizophrenia Disorders And Therapy
Research interests
- Schizophrenia Metabolic Syndrome
Biography
- I graduated cum laude from the Medical University in Bydgoszcz, Poland in 2004.
- I received Ph.D. in psychiatry in 2009 from the Medical University of Lodz, Poland.
- My primary field of interest is metabolic syndrome induced by psychotropic medications and mechanisms underlying metabolic changes induced by psychotropic medications.
- Currently, I am mostly focused on disturbances in central and peripheral homeostasis-regulating neuropeptides in subjects treated with atypical antipsychotics and relationship between bioelectrical impedance analysis, positive and negative symptoms severity and cognitive deficits in subjects with schizophrenia.
- These are two ongoing projects which primary results have already been published in international journals.
Selected publications
- Mechanisms of the anorexia of aging—a review 2015 cited 188×
- Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia 2021 cited 38×
- Rapidly developing and self‐limiting eosinophilia associated with clozapine 2014 cited 13×
- Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study) 2018 cited 12×
- MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study) 2016 cited 11×
- Circadian Rhythm Genes and Their Association with Sleep and Sleep Restriction 2024 cited 11×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JSDT for your work?
This journal is guided by Adam Wysokinski (Central Clinical Hospital, Lodz, Poland) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.